NCT02267863 - A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions

Acute Myelogenous Leukemia in RelapseAcute Myelogenous Leukemia, Relapsed, AdultAcute Myelogenous Leukemia, AdultAcute Myelogenous LeukemiaHigh Risk Myelodysplasia

Interventions

DRUG

APTO-253

APTO-253 will be given in ascending doses starting at 20 mg/m2 until the maximum tolerated dose or recommended dose is reached.

Trial Locations (13)

14643

University of Rochester; Wilmot Cancer Institute Clinical Trials Office, Rochester

29605

Prisma Health, Institute for Translational Oncology Research, Greenville

30322

Emory University; Winship Cancer Institute, Atlanta

44106

University Hospital, Cleveland

48109

University of Michigan, Ann Arbor

59102

St. Vincent Frontier Cancer Center, Billings

70121

Ochsner Cancer Institute, New Orleans

75246

Baylor Research Institute, Dallas

77030

MD Anderson Cancer Center, Houston

85724

University of Arizona Cancer Center, Tucson

92868

University of California, Irvine, Orange

97239

Oregon Health & Science University, Portland

92093-0698

UC San Diego Moores Cancer Center, La Jolla